RxSight (RXST)
(Delayed Data from NSDQ)
$61.15 USD
+0.56 (0.92%)
Updated May 24, 2024 04:00 PM ET
After-Market: $61.22 +0.07 (0.11%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RXST 61.15 +0.56(0.92%)
Will RXST be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for RXST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXST
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
RXST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
What's in the Offing for Brainsway (BWAY) in Q4 Earnings?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Other News for RXST
Do You Have Your Eye On Vision Care Stocks?
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
What's Driving Establishment Labs Holdings Inc's Surprising 34% Stock Rally?
J.P. Morgan Sticks to Its Buy Rating for RxSight (RXST)
RxSight price raises equity at $56 per share